LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fermé

3.73 -5.09

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.59

Max

3.92

Chiffres clés
By Trading Economics
Revenu	-136K -35M
BPA	-0.503
Employés	106
EBITDA	-619K -38M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+75.88% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-11M 283M
Ouverture précédente	8.82
Clôture précédente	3.73

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juin 2026, 23:22 UTC

Résultats

Principaux Mouvements du Marché

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 juin 2026, 23:09 UTC

Actions en Tendance

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 juin 2026, 20:51 UTC

Résultats

Costco Reports 15% Sales Growth in May

3 juin 2026, 20:43 UTC

Résultats

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 juin 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 juin 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juin 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 juin 2026, 23:15 UTC

Market Talk

Résultats

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 juin 2026, 22:08 UTC

Actions en Tendance

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 juin 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 juin 2026, 21:18 UTC

Résultats

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 juin 2026, 21:15 UTC

Résultats

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 juin 2026, 21:13 UTC

Résultats

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 juin 2026, 21:13 UTC

Résultats

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 juin 2026, 21:12 UTC

Résultats

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 juin 2026, 21:09 UTC

Résultats

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 juin 2026, 21:03 UTC

Résultats

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 juin 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 juin 2026, 20:43 UTC

Résultats

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 juin 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 juin 2026, 20:37 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 juin 2026, 20:35 UTC

Résultats

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 juin 2026, 20:17 UTC

Résultats

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 juin 2026, 20:17 UTC

Résultats

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 juin 2026, 20:15 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Adj EPS $2.44 >AVGO

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q EPS $1.91 >AVGO

3 juin 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Rev $22.19B >AVGO

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

75.88% hausse

Prévisions sur 12 Mois

Moyen 7 USD 75.88%

Haut 10 USD

Bas 4 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.